TGFB1 and diabetic kidney disease: With the continuous improvement and progress of technology, artificially collecting or preparing stem cell-derived exosomes containing many beneficial components, such as miR-16-5p, miR-215-5p, miR-486, miR-26a-5p, miR-25-3p, miR-93-5p, etc., or preparing exosomes containing inhibitors of identified harmful components, such as miR-21a-5p, TGF-β, etc., for the clinical treatment of podocyte injury is expected to be a major breakthrough in the field of DKD prevention.